Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194,748 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Sarraju A, et al. Among authors: li j. Am Heart J. 2021 Mar;233:141-148. doi: 10.1016/j.ahj.2020.12.008. Epub 2020 Dec 22. Am Heart J. 2021. PMID: 33358942 Clinical Trial.
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Cannon CP, et al. Among authors: li jw. Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11. Circulation. 2020. PMID: 31707795 Clinical Trial. No abstract available.
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.
Li C, Zhou Z, Neuen BL, Yu J, Huang Y, Young T, Li J, Li L, Perkovic V, Jardine MJ, Keay L, Markoulli M, Rosenthal N, Capuano G, Yavin Y, Neal B, Arnott C. Li C, et al. Among authors: li j, li l. Diabetes Obes Metab. 2021 Jan;23(1):252-257. doi: 10.1111/dom.14197. Epub 2020 Oct 13. Diabetes Obes Metab. 2021. PMID: 32954617
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Yu J, Zhou Z, Mahaffey KW, Matthews DR, Neuen BL, Heerspink HJL, Jardine MJ, Li J, Perkovic V, Neal B, Arnott C. Yu J, et al. Among authors: li j. Int J Cardiol. 2021 Feb 1;324:165-172. doi: 10.1016/j.ijcard.2020.09.050. Epub 2020 Sep 24. Int J Cardiol. 2021. PMID: 32979427
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial.
Oshima M, Neuen BL, Li J, Perkovic V, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Mahaffey KW, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Jardine MJ, Heerspink HJL. Oshima M, et al. Among authors: li j. J Am Soc Nephrol. 2020 Dec;31(12):2925-2936. doi: 10.1681/ASN.2020050723. Epub 2020 Sep 30. J Am Soc Nephrol. 2020. PMID: 32998938 Free PMC article. Clinical Trial.
194,748 results
You have reached the last available page of results. Please see the User Guide for more information.